期刊
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
卷 27, 期 4, 页码 509-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.coms.2015.06.003
关键词
Medication-related osteonecrosis of the jaws; Frequency; Risk factors; Zolendronate; Oral bisphosphonates; Antiresorptive medications; Antiangiogenic agents
This article provides the best current frequency estimate of medication-related osteonecrosis of the jaws (MRONJ) and identifies factors associated with the risk of developing osteonecrosis of the jaw (ONJ) among patients exposed to relevant medications (ie, antiresorptive or antiangiogenic agents). MRONJ is a rare but serious complication of cancer treatment or osteoporosis management. This review confirms that antiresorptive medications such as oral or intravenous bisphosphonates and denosumab are the most common risk factors for developing ONJ. The risk of MRONJ is greater in patients with cancer than in those receiving antiresorptive treatments for osteoporosis by a factor of 10.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据